red blood cells

Bristol Myers Squibb

Pharma

BMS' Reblozyl, chasing $4B sales target, wins key FDA expansion

The first-line anemia use in MDS represents a key milestone as Bristol Myers targets $4 billion in peak sales for the new medicine.

Zoey Becker Aug 29, 2023 11:23am

airplane divert change block no reject direction oath

Erytech pivots to drug delivery after lead candidate collapses

Nov 22, 2022 9:15am

Bristol Myers Squibb

BMS scores a topline treat in Reblozyl phase 3 study

Oct 31, 2022 12:00pm